Arthritis Report March 2017

17 March 2017

In this report we highlight some of the major recent developments, important catalysts and current trends occurring in the arthritis drug development field.

Included in this report:

Investigative News
  • Humira biosimilars unlikely to launch before Amgen’s Amjevita or by 2018 - legal experts
  • Lilly’s Baricitinib uptake faces barrier despite superior RA data, pricing below Xeljanz, Humira the smarter strategy – experts
  • Regeneron/Sanofi’s sarilumab not expected to steal significant RA market from Roche’s Actemra – experts
  • Regeneron/Sanofi’s sarilumab unlikely to nab front-line status from anti-TNFs despite promise – experts
  • Axsome’s AXS-02 oral option unimpressive over IV for osteoarthritis with bone marrow lesions – experts
  • Axsome’s oral drug for osteoarthritis with BML has experts lukewarm on Phase III with scant data
  • Cara’s CR845 pain data in osteoarthritis triggers Phase IIb expert optimism for 5mg dose, long-term safety questions
  • Cara’s CR845 for OA pain has enough market demand despite lukewarm efficacy expectations – experts
  • Eli Lilly’s Taltz likely to match Novartis’ Cosentyx in psoriatic arthritis treatment paradigm, slight edge debated – experts
  • And more
Data Analysis
  • Graph 1: Pharma and Biotech Sponsored Trial Initiations Involving a Drug or Biologic from 2012-2016
  • Graph 2: Number of Drugs Currently in Clinical Development
  • Graph 3: Global Estimated Sales for Select JAK Inhibitors from 2017-2023
  • Graph 4: Global Estimated Sales for Key Approved TNF Inhibitors from 2017-2021
  • Graph 5: Estimated Sales for Select Anti-IL-6 Agents from 2017-2021
  • Graph 6: Global Estimated Arthritis-Specific Cosentyx Sales from 2017-2021
  • Graph 7: Global Estimated Psoriatic Arthritis-Specific Taltz Sales 2018-2020
  • And more